vs

Side-by-side financial comparison of Immunocore Holdings plc (IMCR) and Proto Labs Inc (PRLB). Click either name above to swap in a different company.

Proto Labs Inc is the larger business by last-quarter revenue ($136.5M vs $104.5M, roughly 1.3× Immunocore Holdings plc). On growth, Immunocore Holdings plc posted the faster year-over-year revenue change (24.3% vs 12.1%). Proto Labs Inc produced more free cash flow last quarter ($8.4M vs $-35.5M). Over the past eight quarters, Immunocore Holdings plc's revenue compounded faster (21.7% CAGR vs 3.3%).

Immunocore is a global commercial-stage biotechnology company, based in Oxfordshire, which researches and develops biological drugs using soluble T-cell receptor technology.

Protolabs is a company that provides rapid manufacturing of 3D printed, CNC-machined, sheet metal, and injection-molded custom parts for prototyping and production. Markets like medical devices, aerospace, electronics, appliances, automotive and consumer products use these parts. Protolabs' headquarters are located in Maple Plain, Minnesota, with Minnesota-based manufacturing facilities in Plymouth, Brooklyn Park, and Rosemount, along with additional facilities in Nashua, New Hampshire and Ca...

IMCR vs PRLB — Head-to-Head

Bigger by revenue
PRLB
PRLB
1.3× larger
PRLB
$136.5M
$104.5M
IMCR
Growing faster (revenue YoY)
IMCR
IMCR
+12.2% gap
IMCR
24.3%
12.1%
PRLB
More free cash flow
PRLB
PRLB
$43.9M more FCF
PRLB
$8.4M
$-35.5M
IMCR
Faster 2-yr revenue CAGR
IMCR
IMCR
Annualised
IMCR
21.7%
3.3%
PRLB

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IMCR
IMCR
PRLB
PRLB
Revenue
$104.5M
$136.5M
Net Profit
Gross Margin
97.4%
44.2%
Operating Margin
-18.8%
5.0%
Net Margin
Revenue YoY
24.3%
12.1%
Net Profit YoY
EPS (diluted)
$-0.61
$0.25

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IMCR
IMCR
PRLB
PRLB
Q4 25
$104.5M
$136.5M
Q3 25
$103.7M
$135.4M
Q2 25
$98.0M
$135.1M
Q1 25
$93.9M
$126.2M
Q4 24
$84.1M
$121.8M
Q3 24
$80.2M
$125.6M
Q2 24
$75.4M
$125.6M
Q1 24
$70.5M
$127.9M
Net Profit
IMCR
IMCR
PRLB
PRLB
Q4 25
Q3 25
$-177.0K
$7.2M
Q2 25
$-10.3M
$4.4M
Q1 25
$5.0M
$3.6M
Q4 24
Q3 24
$8.7M
$7.2M
Q2 24
$-11.6M
$4.5M
Q1 24
$-24.4M
$5.3M
Gross Margin
IMCR
IMCR
PRLB
PRLB
Q4 25
97.4%
44.2%
Q3 25
99.5%
45.3%
Q2 25
98.9%
44.3%
Q1 25
99.1%
44.1%
Q4 24
99.6%
42.7%
Q3 24
99.4%
45.6%
Q2 24
97.7%
45.0%
Q1 24
99.7%
44.9%
Operating Margin
IMCR
IMCR
PRLB
PRLB
Q4 25
-18.8%
5.0%
Q3 25
-6.9%
6.5%
Q2 25
-15.2%
3.7%
Q1 25
-3.9%
3.6%
Q4 24
-23.1%
-1.2%
Q3 24
-10.6%
6.8%
Q2 24
-21.2%
4.8%
Q1 24
-37.6%
5.3%
Net Margin
IMCR
IMCR
PRLB
PRLB
Q4 25
Q3 25
-0.2%
5.3%
Q2 25
-10.5%
3.3%
Q1 25
5.4%
2.9%
Q4 24
Q3 24
10.9%
5.7%
Q2 24
-15.4%
3.6%
Q1 24
-34.7%
4.1%
EPS (diluted)
IMCR
IMCR
PRLB
PRLB
Q4 25
$-0.61
$0.25
Q3 25
$0.00
$0.30
Q2 25
$-0.20
$0.18
Q1 25
$0.10
$0.15
Q4 24
$-0.47
$-0.01
Q3 24
$0.17
$0.29
Q2 24
$-0.23
$0.18
Q1 24
$-0.49
$0.20

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IMCR
IMCR
PRLB
PRLB
Cash + ST InvestmentsLiquidity on hand
$864.2M
$128.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$381.0M
$673.9M
Total Assets
$1.1B
$763.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IMCR
IMCR
PRLB
PRLB
Q4 25
$864.2M
$128.1M
Q3 25
$892.4M
$119.2M
Q2 25
$882.8M
$103.2M
Q1 25
$837.0M
$96.8M
Q4 24
$820.4M
$103.1M
Q3 24
$901.3M
$100.5M
Q2 24
$859.6M
$112.9M
Q1 24
$832.8M
$109.7M
Total Debt
IMCR
IMCR
PRLB
PRLB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$438.7M
Q2 24
$452.5M
Q1 24
$452.5M
Stockholders' Equity
IMCR
IMCR
PRLB
PRLB
Q4 25
$381.0M
$673.9M
Q3 25
$396.6M
$664.7M
Q2 25
$388.5M
$664.7M
Q1 25
$378.5M
$656.8M
Q4 24
$360.7M
$670.2M
Q3 24
$377.8M
$680.0M
Q2 24
$359.1M
$685.2M
Q1 24
$359.5M
$687.3M
Total Assets
IMCR
IMCR
PRLB
PRLB
Q4 25
$1.1B
$763.4M
Q3 25
$1.1B
$756.9M
Q2 25
$1.1B
$743.3M
Q1 25
$1.0B
$737.5M
Q4 24
$1.0B
$743.5M
Q3 24
$1.1B
$753.8M
Q2 24
$1.0B
$758.2M
Q1 24
$994.0M
$769.8M
Debt / Equity
IMCR
IMCR
PRLB
PRLB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
1.16×
Q2 24
1.26×
Q1 24
1.26×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IMCR
IMCR
PRLB
PRLB
Operating Cash FlowLast quarter
$-32.7M
$16.5M
Free Cash FlowOCF − Capex
$-35.5M
$8.4M
FCF MarginFCF / Revenue
-34.0%
6.2%
Capex IntensityCapex / Revenue
2.8%
5.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-15.1M
$59.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IMCR
IMCR
PRLB
PRLB
Q4 25
$-32.7M
$16.5M
Q3 25
$-4.5M
$29.1M
Q2 25
$26.0M
$10.6M
Q1 25
$435.0K
$18.4M
Q4 24
$-14.0M
$17.3M
Q3 24
$21.1M
$24.8M
Q2 24
$23.5M
$14.4M
Q1 24
$-4.6M
$21.3M
Free Cash Flow
IMCR
IMCR
PRLB
PRLB
Q4 25
$-35.5M
$8.4M
Q3 25
$-5.2M
$25.0M
Q2 25
$25.6M
$9.1M
Q1 25
$137.0K
$17.1M
Q4 24
$-17.5M
$16.5M
Q3 24
$20.3M
$23.2M
Q2 24
$23.1M
$10.2M
Q1 24
$-5.0M
$18.8M
FCF Margin
IMCR
IMCR
PRLB
PRLB
Q4 25
-34.0%
6.2%
Q3 25
-5.0%
18.5%
Q2 25
26.1%
6.7%
Q1 25
0.1%
13.6%
Q4 24
-20.9%
13.5%
Q3 24
25.3%
18.5%
Q2 24
30.7%
8.2%
Q1 24
-7.1%
14.7%
Capex Intensity
IMCR
IMCR
PRLB
PRLB
Q4 25
2.8%
5.9%
Q3 25
0.7%
3.0%
Q2 25
0.4%
1.1%
Q1 25
0.3%
1.0%
Q4 24
4.3%
0.7%
Q3 24
1.0%
1.2%
Q2 24
0.4%
3.3%
Q1 24
0.6%
2.0%
Cash Conversion
IMCR
IMCR
PRLB
PRLB
Q4 25
Q3 25
4.03×
Q2 25
2.39×
Q1 25
0.09×
5.11×
Q4 24
Q3 24
2.42×
3.44×
Q2 24
3.18×
Q1 24
4.05×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IMCR
IMCR

Segment breakdown not available.

PRLB
PRLB

CNC Machining Firstcut$65.5M48%
Injection Molding Protomold$47.6M35%
Three D Printing Fineline$18.8M14%
Sheet Metal$4.4M3%

Related Comparisons